FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.; FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.; FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.; FY 2026 Appropriations for DOD and HHS, focused on funding for development and procurement of medical countermeasures and antibiotics.
Issues related to the pharmaceutical industry.; Issues related to the pharmaceutical industry.
Registered Lobbyists (2)
MICHAEL CORCORAN ●NEWROBERT BLAIR ●NEW
IDs
Filing UUID:a8b3d74c-0214-4f8a-9cf6-b7b1f2b0d8fc
Registrant ID:401109009
Client ID:64784
2025-03-11
FORBES-TATE
ANAVEX LIFE SCIENCES
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues related to biopharmaceutical innovation
Registered Lobbyists (4)
ARTHUR SIDNEY ●NEW— LD & Chief Counsel, Rep. Jackson Lee (2008-2009); Chief of staff and chief counsel, Rep. Johnson (2009-2020)BARRETT THORNHILL ●NEW— Legislative Assistant, Sen. Mike Crapo (2003-2006)RICHARD LOPEZ ●NEWWESLEY WELCH ●NEW— Legislative Director, Sen. Richard Shelby (2005-2007); Legislative Assistant, Sen. Richard Shelby (2002-2005)
Equitable Access to Community Pharmacist Services Act; proposals to reform domestic and international tax structures; infant formula; Equitable Access to Community Pharmacist Services Act; proposals to reform domestic and international tax structures; infant formula; Equitable Access to Community Pharmacist Services Act; proposals to reform domestic and international tax structures; infant formula; Equitable Access to Community Pharmacist Services Act; proposals to reform domestic and international tax structures; infant formula
Registered Lobbyists (5)
CHANDA BETOURNEY ●NEW— Dep. Staff Director and Chief Counsel, Senate Appropriations Cmt; Chief Counsel Civil Law and Oversight, Sen. Counsel, Sen. Judiciary Cmt; Leg Asst. and Projects Dir., Leg. Corresp., Senator LeahyCHRISTOPHER BUKI ●NEW— Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinleyKRISTI REMINGTON ●NEW— Deputy Assistant Attorney General, US Department of Justice; Senior Counsel, House Government Reform CommitteeMARTIN REISER ●NEW— Policy Director, Republican Whip Steve Scalise, professional staff House Ways and Means Committee, Chief of Staff, Rep. Dan Miller, Budget Associate, House Budget CommitteeMATT BRAVO ●NEW— Director of Floor Operations for Maj. Whip Steve Scalise; Prof Staff, E&C; Floor Asst to Maj. Leader Eric Cantor
IDs
Filing UUID:33945617-b9a6-4b74-ad05-03e37b2255e3
Registrant ID:400774330
Client ID:64754
2025-03-09
LMH STRATEGIC SOLUTIONS
ALNYLAM PHARMACEUTICALS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Home Infusions Issues.
Registered Lobbyists (1)
ALANNA TEMME ●NEW— Legislative Director, U.S. Representative Jon Porter
IDs
Filing UUID:2f0b7936-311f-42dc-aa4c-5f395aecb568
Registrant ID:401108183
Client ID:64726
2025-03-07
THEGROUP DC, LLC
CVS HEALTH (AND SUBSIDIARIES)
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues related to pharmacy services and other health issues.; Issues related to pharmacy services and other health issues.
Registered Lobbyists (2)
ESTEFANIA RODRIGUEZ ●NEW— Sr. Legis. Assistant, November 2017-September 2018, Rep. Barragan.KWABENA NSIAH ●NEW— Congressional Black Caucus, Policy Director; Rep. Richmond, Chief of Staff.
IDs
Filing UUID:cf634968-1c9d-4054-8284-a10305953a6f
Registrant ID:401103834
Client ID:64697
2025-03-07
CAPITOL COUNSEL LLC
ALNYLAM PHARMACEUTICALS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.
Registered Lobbyists (2)
JEFFREY CARROLL ●NEW— Staff Director House Energy and Commerce Committee; Chief of Staff, Rep. Frank Pallone.JOHN MARTIN ●NEW— Associate Commissioner, FDA; Legislative Director, Sen. Tom Cotton; Legislative Assistant; Sen. Tom Cotton; Legislative Assistant, Representative Tom Cotton.
IDs
Filing UUID:6a6c0fb1-21e4-4ec7-8477-0e76589a89b4
Registrant ID:313715
Client ID:64701
2025-03-07
CAPITOL COUNSEL LLC
ALNYLAM PHARMACEUTICALS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development.
Registered Lobbyists (2)
JEFFREY CARROLL ●NEW— Staff Director House Energy and Commerce Committee; Chief of Staff, Rep. Frank Pallone.JOHN MARTIN ●NEW— Associate Commissioner, FDA; Legislative Director, Sen. Tom Cotton; Legislative Assistant; Sen. Tom Cotton; Legislative Assistant, Representative Tom Cotton.
IDs
Filing UUID:6ef1892c-d10b-43af-894c-a7cc9fd7a01d
Registrant ID:313715
Client ID:64701
2025-03-05
MEDSECUREAN.COM
INDIAN PHARMACEUTICAL ALLIANCE(FORMERLY INDIAN PHARMACEUTICAL ASSOCIATION)
$15,000
$0
Filing Details
Type: ld2 • Year: 2025 Q1
Specific Issues
The Indian Pharmaceutical Alliance (IPA) is dedicated to ensuring a level playing field in the U.S. pharmaceutical market and upholding the principles of the U.S. Hatch-Waxman Act to balance innovation with access. IPA members supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures. IPA actively supports targeted reforms to enhance the sustainability of the generic drug industry. Specifically, IPA advocates for substantial reforms of Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) to ensure transparent pricing and fair market practices that benefit consumers. Additionally, IPA champions efforts to close loopholes in the Hatch-Waxman Act that delay generic drug entry, facilitating timely access to affordable medications. These reforms are crucial for maintaining industry sustainability, reducing healthcare costs, and ensuring that effective, affordable treatment options remain accessible to all Americans. IPAs efforts underscore its pivotal role in promoting a healthy future for all Americans through enhanced access to affordable medicine and a robust, enduring pharmaceutical industry.; Indian Pharmaceutical Alliance is a trade association in India, representing key innovative and affordable medicine manufacturers. These manufacturers supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures.; The Indian Pharmaceutical Alliance (IPA) actively supports targeted reforms in the U.S. healthcare system to ensure the sustainability of the generic drug industry. IPA advocates for meaningful reforms of Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) to secure transparent pricing and equitable market practices that directly benefit consumers. Moreover, IPA champions efforts to close loopholes in the Hatch-Waxman Act that impede timely generic drug market entry from remving patent thickets to generic first policies. These strategic initiatives are crucial for maintaining industry sustainability, reducing U.S. healthcare costs, and ensuring that effective, affordable treatment options remain accessible to all Americans. IPAs commitment to these reforms underscores its dedication to fostering a robust and enduring U.S.generic drug sector.
Government Entities
Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office, Natl Economic Council (NEC), Natl Security Council (NSC), Centers For Medicare and Medicaid Services (CMS)
Registered Lobbyists (1)
KATHLEEN JAEGER ●NEW
IDs
Filing UUID:e0df904c-d6d1-4144-8b37-f405d3beb9e3
Registrant ID:401108536
Client ID:60141
2025-02-28
CLARK HILL PUBLIC STRATEGIES LLC
WEST PHARMACEUTICAL SERVICES, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Matters relating to tariffs, pharmaceuticals, and the medical industry.; Matters relating to tariffs, pharmaceuticals, and the medical industry.; Matters relating to tariffs, pharmaceuticals, and the medical industry.
Registered Lobbyists (1)
ANTHONY CAMPAU ●NEW— Chief of Staff and Counselor, Office of Information and Regulatory Affairs (OIRA), U.S. Office of Management and Budget (OMB), Executive Office of the President (EOP); Transition Staff, OMB/OIRA; Regulatory Reform Team, Presidential Transition Team.
IDs
Filing UUID:20357dfd-3f25-4c28-b09f-973711775d29
Registrant ID:401106670
Client ID:64539
2025-02-27
FORWARD GLOBAL
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Pharmacy Benefit Managers (PBM) provisions to be included in potential congressional legislation, including but not limited to the Continuing Resolution; engagement with the Trump Administration, including but not limited to, the Office of Public Engagement, Domestic Policy Council, and Department of Health and Human Services; Pharmacy Benefit Managers (PBM) provisions to be included in potential congressional legislation, including but not limited to the Continuing Resolution; engagement with the Trump Administration, including but not limited to, the Office of Public Engagement, Domestic Policy Council, and Department of Health and Human Services; Pharmacy Benefit Managers (PBM) provisions to be included in potential congressional legislation, including but not limited to the Continuing Resolution; engagement with the Trump Administration, including but not limited to, the Office of Public Engagement, Domestic Policy Council, and Department of Health and Human Services
Registered Lobbyists (6)
AMAN TUNE ●NEWLEAH CHARETTE ●NEWLIZZY IRWIN ●NEWMICHAEL RUBINO ●NEW— Senior Advisor to the Secretary, Health and Human ServicesNOE GARCIA ●NEW— Senior Policy Advisor, Senate Majority Leader, Bill Frist; Associate Political Director, The White House; Senior Advisor, Public Affairs, US Treasury Department; Public Liaison, US Treasury Department; Legislative Assistant, Rep. Kay HutchisonTHOMAS MATHIASEN ●NEW
IDs
Filing UUID:1faa8bea-9c34-4cdb-838d-73464ee8ccd2
Registrant ID:401105597
Client ID:64514
2025-02-24
SALT POINT STRATEGIES
VERTEX PHARMACEUTICALS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Non-opioid pain relief and drug pipeline issues.
Registered Lobbyists (1)
ADAM BUCKALEW ●NEW— Covered Official Positions Continued: Deputy Chief of Staff, U.S. Rep. Markwayne Mullin (R-OK); Communications Director & Legislative Assistant, U.S. Rep. Gregg Harper (R-MS)
IDs
Filing UUID:bdd89876-5014-4331-878a-895da3a75cb8
Registrant ID:401105514
Client ID:64435
2025-02-20
CHECKMATE GOVERNMENT RELATIONS
NOVO NORDISK, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues and legislation related to anti-obesity medications, drug pricing, and pharmaceutical supply chain.
Registered Lobbyists (3)
CHARLES MCDOWELL ●NEWFREDERICK VAUGHAN ●NEW— Principal Deputy Asst. Secretary, Treasury Dept.; Deputy Asst. Secretary, Treasury Dept.; Senior Counsel, House Financial Services Cmte.; Associate Director, The White House; Confidential Asst., Office of Management & Budget; Writer, The White HouseJOHN EASTERLING ●NEW
IDs
Filing UUID:957ce2c3-d4a2-46c8-a810-fc3d543ce7ff
Registrant ID:401109039
Client ID:64386
2025-02-19
SKYLINE CAPITOL LLC
SEEK LABS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues regarding healthcare solutions that bridge gaps between patients, providers and treatments. Increasing access to diagnostic and pharmaceutical solutions and tools.
Registered Lobbyists (2)
CLAY WHITE ●NEW— Chief of Staff, Leg Director - Congressman Chris Stewart; Leg Director, Leg Asst - Congressman Jason ChaffetzLIAM ANDERSON ●NEW— Comm Director, Rep Mike Garcia; Comm Director Rep Chris Stewart; Staff, Rep Mike Gallagher; Staff, HHS Sec Alex Azar
IDs
Filing UUID:c280fb57-0aad-4d33-9f5a-9ae371ae5ba4
Registrant ID:401108050
Client ID:64346
2025-02-19
BOCKORNY GROUP, INC.
CVS HEALTH INC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Pharmacy
Registered Lobbyists (1)
DAVID BOCKORNY ●NEW
IDs
Filing UUID:76167573-eb80-4cde-829a-b5bf38dfd8e6
Registrant ID:289773
Client ID:177453
2025-02-18
FOLEY HOAG LLP
TONIX PHARMACEUTICALS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues related to reimbursement for non-opioid alternatives.
Registered Lobbyists (1)
ELI GREENSPAN ●NEW
IDs
Filing UUID:5dd8fcdd-3176-4ca2-ae25-1d3a31f387d5
Registrant ID:79610
Client ID:170730
2025-02-14
OGR
AMNEAL PHARMACEUTICALS LLC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Advocate for the importance of maintaining strong domestic manufacturing industry.
Registered Lobbyists (1)
TIMOTHY MCGIVERN ●NEW— Chief of Staff, Senator Sam Brownback
General issues impacting retail industry and issues related to pharmacy services.; General issues impacting retail industry and issues related to pharmacy services.
Registered Lobbyists (2)
BENJAMIN QUAYLE ●NEW— Member of the U.S. House of RepresentativesRASHID HALLAWAY ●NEW— Legislative Assistant, U.S. Senator Evan Bayh
Issues related to the provider status of pharmacists under Medicare Part B; Issues related to the provider status of pharmacists under Medicare Part B
Registered Lobbyists (6)
ASHLEY DAVIS ●NEW— Special Assistant to the Homeland Security Director, Executive Office of the President; Deputy Director of Management and Administration, Executive Office of the PresidentCHRISTOPHER BUKI ●NEW— Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinleyCRAIG KALKUT ●NEW— Staff Director/Chief Counsel, Senate Judiciary Committee; Analyst, Senate Budget Committee; Counsel, Legislative Assistant, Special Assistant to Chief Staff, Senator Kent ConradKRISTI REMINGTON ●NEW— Deputy Assistant Attorney General, US Department of Justice; Senior Counsel, House Government Reform CommitteeMALLOY MCDANIEL ●NEW— Policy Advisor, Senate Minority Leader Mitch McConnell; Whip Liaison, Senate Majority Whip Mitch McConnell; Floor Assistant, Senate Majority Leader Trent Lott; Cloakroom Assistant, Office of the Republican SecretarySHIMON STEIN ●NEW— Senior Policy Advisory, House Majority Leader Eric Cantor, Program Manager, US Department of Justice, Legislative Correspondent, Senator John Ashcroft; Paid Intern, Representative Robert Aderholt
IDs
Filing UUID:7bd82fbb-7052-43a7-83b1-f45096f6f397
Registrant ID:400774330
Client ID:64050
2025-02-07
S-3 GROUP
HEALTH INDUSTRY DISTRIBUTORS ASSOCIATION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues relating to the distribution of health care products, competitive bidding, pharmaceutical pedigree, and medical device licensure
Registered Lobbyists (6)
ASHLEY DAVIS ●NEW— Special Assistant to the Homeland Security Director, Executive Office of the President; Deputy Director of Management and Administration, Executive Office of the PresidentCHRISTOPHER BUKI ●NEW— Staff Assistant/Legislative Correspondent, Representative John Culberson; Legislative Assistant/Senior Legislative Assistant, Representative Bill Shuster; Legislative Director/Deputy Chief of Staff, Representative David McKinleyCRAIG KALKUT ●NEW— Staff Director/Chief Counsel, Senate Judiciary Committee; Analyst, Senate Budget Committee; Counsel, Legislative Assistant, Special Assistant to Chief Staff, Senator Kent ConradKRISTI REMINGTON ●NEW— Deputy Assistant Attorney General, US Department of Justice; Senior Counsel, House Government Reform CommitteeMALLOY MCDANIEL ●NEW— Policy Advisor, Senate Minority Leader Mitch McConnell; Whip Liaison, Senate Majority Whip Mitch McConnell; Floor Assistant, Senate Majority Leader Trent Lott; Cloakroom Assistant, Office of the Republican SecretarySHIMON STEIN ●NEW— Senior Policy Advisory, House Majority Leader Eric Cantor, Program Manager, US Department of Justice, Legislative Correspondent, Senator John Ashcroft; Paid Intern, Representative Robert Aderholt
IDs
Filing UUID:52ae3d96-7e4e-481b-a556-228894830f84
Registrant ID:400774330
Client ID:64063
2025-02-07
THE WASHINGTON TAX & PUBLIC POLICY GROUP
REGENERON PHARMACEUTICALS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Issues related to corporate and international tax
Registered Lobbyists (3)
GREGORY NICKERSON ●NEW— Tax Counsel, Ways and Means Committee; Staff Director, Ways and Means Select Revenue Measures SubcommitteeJAMES PEDROTTI ●NEW— Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Deputy Chief of Staff to Rep. Carol MillerZACHARY PRICE ●NEW— Staff Assistant, Sen. Dan Coats
IDs
Filing UUID:629aae3d-4de0-49d2-b8df-e614d649e301
Registrant ID:294930
Client ID:64079
2025-02-05
CORNERSTONE GOVERNMENT AFFAIRS, INC.
STARFIGHTERS SPACE, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q1
Specific Issues
Increase Starfighters Spaces visibility in front of key federal policymakers in the legislative and executive branches to further build support for space launch, hypersonic testing, and pharmaceutical development.; Increase Starfighters Spaces visibility in front of key federal policymakers in the legislative and executive branches to further build support for space launch, hypersonic testing, and pharmaceutical development.; Increase Starfighters Spaces visibility in front of key federal policymakers in the legislative and executive branches to further build support for space launch, hypersonic testing, and pharmaceutical development.; Increase Starfighters Spaces visibility in front of key federal policymakers in the legislative and executive branches to further build support for space launch, hypersonic testing, and pharmaceutical development.; Increase Starfighters Spaces visibility in front of key federal policymakers in the legislative and executive branches to further build support for space launch, hypersonic testing, and pharmaceutical development.
Registered Lobbyists (9)
ADAM YEZERSKI ●NEW— Professional Staff Member, Senate Committee on Appropriations; Military Legislative Assistant, Senate Member Office (Shelby);Legislative Correspondent, Senate Member Office (Shelby)ANTHONY LAZARSKI ●NEW— Senior Legislative Advisor, Senate Member Office (Inhofe); Professional Staff Member, Senate Armed Services Committee; Military Legislative Assistant, Senate Member Office (Inhofe)CHRISTOPHER HODGSON ●NEW— Legislative Assistant (Scalise), Floor Assistant & Deputy Floor Director for House Majority Whip (Scalise), Deputy Director & Director of Legislative Affairs (Pence)DABNEY HEGG ●NEW— Clerk, Sen Approps Cmte; Prof Staff, Sen Approps Cmte; Sr Prof Staff,Senate Cmte on Commerce, Science, and Transportation; Prof Staff, SenateCmte onCommerce, Science, and Transportation; Leg Asst(Hollings);StaffAsst(Hollings); Intern(Hollings)JOHN CRUMBLISS ●NEWJONATHAN MILLER ●NEWJOSEPH BARTON ●NEW— LA House Member Office (Boehner)MATT SCHNAPPAUF ●NEWMICHAEL FALENCKI ●NEW— Dep Staff Dir, House Transportation & Infrastructure Comm; Staff Dir, Subcomm on Highways & Transit (T&I); Staff Dir, Subcomm on Railroads, Pipelines, & Hazardous Materials (T&I); Legislative Dir, Deputy CoS Staff, House Member Office (S. Graves)